“I wish to confirm that all hypotheses remain open and require further analysis and studies”, says @drtedros about origin of #covid19 at @WHO presser. Calls the origins mission "a very important scientific exercise in very difficult circumstances”.
@DrTedros@WHO "The expert team is working on a summary report which we hope will be published next week”, says @DrTedros.
“The full final report will be published in the coming weeks.”
@DrTedros@WHO “The number of reported cases of #COVID19 globally has declined for the 4th week in a row and the number of deaths also fell for the 2nd consecutive week” says @DrTedros. "This decline appears to be due to countries implementing public health measure more stringently."
@DrTedros@WHO Some people thought a vaccine could not be produced within a year but it happened, says @drtedros.
"Now, some people say that vaccinating, the world is not possible.
They are dead wrong."
@DrTedros@WHO "I'm inviting everyone to join me in a call to action to accelerate production and share technology, so we can produce enough vaccines for the world, and share them equitably”, says @DrTedros.
Quotes Mandela: "it always seems impossible until it's done. "
@DrTedros@WHO WHO held a global meeting this week "to advance our understanding of what is officially called post-COVID condition or long COVID”, says @drtedros. "This was the first in a series of meetings focused on working towards an agreed clinical description of the condition"
@DrTedros@WHO "This illness affects patients with both severe and mild #COVID19”, says @DrTedros. "Part of the challenge is that patients with long COVID can have a range of different symptoms that can be persistent or can come and go.” New case reporting form should help collect more data.
@DrTedros@WHO Q about Ebola in DRC from @HelenBranswell:
3rd case now, says @DrMikeRyan. Sequence data on 1st case could be available this weekend. “It's really important that we understand the origin of this first case and that sequencing data will give us vital information to move forward."
@DrTedros@WHO@HelenBranswell@DrMikeRyan "I think we have been successful in many ways”, says @Peterfoodsafety. Clearer that there was no widespread transmission in or around Wuhan prior to December '19. "We have also been able to trace back all the suppliers of different wild animal products to the market."
@DrTedros@WHO@HelenBranswell@DrMikeRyan@Peterfoodsafety Still far from understanding the origin of #SARSCoV2, pinpointing an intermediary species or finding path how it was transmitted, says @Peterfoodsafety. “We knew from before going there that it would take a long time and a lot of effort to get there, so it's just a start."
@DrTedros@WHO@HelenBranswell@DrMikeRyan@Peterfoodsafety@doctorsoumya Q about giving just one dose of vaccine to people with prior infection.
“More studies are needed, longer follow up is needed to find out how long this kind of protection is going to last”, says @doctorsoumya. For now, WHO guidelines are still to use two doses.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Good news (again) from the UK’s impressive Recovery trial:
Tocilizumab reduced deaths from #COVID19 by about 4% and that was on top of dexamethasone.
It means that giving 25 people this drug on top of the standard of care will lead to one saved life.
Tocilizumab also reduced the need for a mechanical ventilator and shortened the hospital stay.
All of this is from press release for now: recoverytrial.net/news/tocilizum…
Manuscript is working its way through medrxiv right now.
Tocilizumab is an anti-inflammatory drug, an antibody that targets the IL-6 receptor, dampening the immune system. It is used to treat rheumatoid arthritis.
It is also about 100x as expensive as dexamethasone, so it will probably increase the global inequities of this pandemic.
Press conference on what @WHO-convened mission to investigate the origins of #SARSCoV2 found on their China trip is about to start in Wuhan.
(Was originally supposed to start an hour ago before being pushed back)
@WHO After a lengthy introduction of the mission and its terms of reference, Liang Wannian, who leads the Chinese team of the joint mission, says he will now begin to talk about the key findings, starting with molecular epidemiology.
“It seems increasingly clear that manufacturers will have to adjust to the evolution of the virus, taking into account the latest variants for future shots, including boosters”, says @DrTedros at @WHO presser. “We have to be ready to adapt vaccines so they remain effective."
@DrTedros@WHO "These developments highlight why it's so important to scale up manufacturing and rollout vaccines as quickly as possible and as widely as possible to protect people before they're exposed to new variants”, says @drtedros.
@DrTedros@WHO “We need to do everything we can to reduce circulation of the virus with proven public health measures”, says @DrTedros. "Several countries are succeeding in suppressing transmission including those where new variants are circulating."
After #b117 was identified in England and seemed to be taking off there, many people like me started looking at Denmark for clues.
Why Denmark? It sequences a lot! Here is a graph from @ECDC_EU from late December showing EU sequencing (look at B and note that it’s a log-scale):
@ECDC_EU Denmark has actually massively scaled-up its sequencing since then. @MadsAlbertsen85 and his team, who have basically been doing all the sequencing for the whole country, are now getting close to 70% which is about as much as is possible (30% have low virus concentrations).
COVAX facility just published a forecast of what country will receive how much of what #covid19 vaccine in the first half of this year.
Lots of caveats of course. This is mostly AZ vaccine, which does not have emergency use listing yet, for instance. gavi.org/sites/default/…
Big picture:
Countries can expect to receive vaccine to cover on average 3,3% of their population in first half of 2021, "enough to protect the most vulnerable groups such as health care workers”.
Here is “A” to give you an idea (SFP are self financing countries)
Most vaccine here is AstraZeneca’s:
240 million doses of AZ vaccine licensed to Serum Institute of India (SII)
96 million doses directly from AZ (this was supposed to be 153 million, but some shipments delayed to Q3)
„The development of the Sputnik V vaccine has been criticised for unseemly haste, corner cutting, and an absence of transparency. But the outcome reported here is clear and the scientific principle of vaccination is demonstrated ...“ thelancet.com/journals/lance…
Authors end that comment in Lancet by pointing that the result „means another vaccine can now join the fight to reduce the incidence of #COVID19“.